Orforglipron
First oral non-peptide GLP-1 receptor agonist for diabetes and obesity
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
0.8 – 17.2 mg
0.8 mg once daily
At least 30 days
5.5 mg once daily
Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mg
9–17.2 mg once daily
Ongoing; each step after at least 30 days on the previous dose
Compound profile
Orforglipron scientific & efficacy data
Weight Management
Peptide profile
Strong human trials
Orforglipron
0.8 mg once daily · Once daily
Molecular formula
C48H48F2N10O5
- Mol. weight
- 883.0 Da
- CAS number
- 2212020-52-3
- PubChem
- 137319706
- Developed · FDA approved 1 April 2026 (NDA 220934, FOUNDAYO)
- Eli Lilly and Company (discovered by Chugai Pharmaceutical)
Eli Lilly and Company
Amino acid sequence
Not applicable — non-peptide small moleculeWeight Management
11.1% average weight loss at 72 weeks on the top 17.2 mg dose against 2.1% on placebo, with 54.5% losing at least 10% of body weight (13% on placebo), in 3,127 adults without diabetes — from a once-daily pill [7]
Blood Sugar Control
HbA1c reduction of 2.2% in ACHIEVE-3 trial, demonstrating superiority over oral semaglutide (1.4%) with nearly 3x more patients reaching target HbA1c <7%
Cardiovascular Health
50.6% reduction in hsCRP inflammatory marker at 36 mg dose, along with improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure
Dosing
How much Orforglipron do I take?
0.8 mg once daily, titrated to 9–17.2 mg once daily · once daily, with or without food
0.8 – 17.2 mg
Once daily, with or without food
Covers all 3 documented dose levels · timing · dose-adjustment guidance.
Every documented dose level
| Phase | Dose | Frequency |
|---|---|---|
| At least 30 days | 0.8 mg once daily | Once daily, with or without food |
| Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mg | 5.5 mg once daily | Once daily, with or without food |
| Ongoing; each step after at least 30 days on the previous dose | 9–17.2 mg once daily | Once daily, with or without food |
Suitability
Is Orforglipron right for me?
Best for oral glp-1 receptor agonism without injection burden & weight management in obesity with or without type 2 diabetes
Best for
Oral GLP-1 receptor agonism without injection burden
Orforglipron is particularly well-suited for individuals focused on oral glp-1 receptor agonism without injection burden. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Weight management in obesity with or without type 2 diabetes
Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Glycemic control in type 2 diabetes as add-on to metformin
Orforglipron is particularly well-suited for individuals focused on glycemic control in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cardiovascular risk reduction through weight loss and metabolic improvements
Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Orforglipron with similar peptides to find the best fit for your goals.
Administration
How do I use Orforglipron?
oral
Route
Orforglipron is administered oral—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is Orforglipron safe?
4 common side effects · 2 serious
Orforglipron is FDA approved as FOUNDAYO (April 2026) for long-term weight management.
[7][8] Its label carries a boxed warning on thyroid C-cell tumours seen with GLP-1 receptor agonists in rodents — orforglipron itself is not active in rats or mice and caused no rodent tumours — and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2.
[7] In the two phase 3 weight trials, gastrointestinal reactions affected 60–69% of patients against 37% on placebo, mostly mild or moderate and most frequent during dose escalation; 8% stopped treatment for adverse reactions against 3% on placebo.
[7] Labelled warnings also cover acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycaemia with insulin or a sulfonylurea, hypersensitivity, diabetic retinopathy complications, gallbladder disease and pulmonary aspiration under anaesthesia. [7]
The FDA label rests on two 72-week, placebo-controlled phase 3 trials in 4,740 adults: 3,127 without diabetes and 1,613 with type 2 diabetes.
[7] Mean weight change at 72 weeks was −7.4%, −8.3% and −11.1% on 5.5, 9 and 17.2 mg against −2.1% on placebo without diabetes, and −5.1%, −7.0% and −9.6% against −2.5% with type 2 diabetes.
[7] In the diabetes trial, glucose below 54 mg/dL occurred in 2% on orforglipron against 0.2% on placebo, and hypoglycaemia was reported by 7% of those also taking a sulfonylurea against 0.5% of those not. [7]
Less common
These typically resolve with continued use or dose adjustment.
Common side effects · experienced by some users
Nausea
The most commonly reported adverse event, consistent with the GLP-1 receptor agonist class. Dose-dependent and most frequent during dose escalation. [7] Generally mild to moderate.
Management: Gradual dose escalation minimizes incidence. Symptoms typically improve with continued treatment. Smaller, more frequent meals may help. If severe, pause escalation at current dose level.
Constipation
Common gastrointestinal effect related to GLP-1R-mediated slowing of gut motility. Reported across dose levels in Phase 3 trials. [7]
Management: Increase dietary fiber and fluid intake. Mild laxatives if needed. Usually manageable and does not require dose adjustment.
Diarrhea
GI disturbance from GLP-1 receptor activation affecting intestinal motility and secretion. Generally transient and self-limiting.
Management: Maintain hydration. Usually resolves without intervention. Contact prescriber if persistent or severe.
Vomiting
Occurs alongside nausea, particularly during dose titration. Related to central and peripheral GLP-1R activation.
Management: Slow dose escalation. Ensure adequate hydration. Anti-emetics if needed. Temporarily hold dose increase if recurrent.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Orforglipron
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Orforglipron should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Metformin — Complementary mechanisms — metformin provides insulin sensitization while orforglipron offers GLP-1R-mediated glucose-dependent insulin secretion and appetite suppression
- Safe:SGLT2 Inhibitors — Independent glucose-lowering via renal glucose excretion with demonstrated cardiorenal benefits complements oral GLP-1 agonism
- Safe:Dietary Modification — Caloric restriction synergizes with orforglipron's appetite suppression for enhanced weight loss outcomes
With medications
- Caution:Injectable GLP-1 Receptor Agonists — Redundant GLP-1R activation with no additional benefit and increased gastrointestinal adverse events
- Caution:DPP-4 Inhibitors — Overlapping incretin pathway stimulation provides minimal additional efficacy when combined with a direct GLP-1R agonist
- Caution:Sulfonylureas — Increased hypoglycemia risk from non-glucose-dependent insulin secretion combined with GLP-1R-mediated insulin release
With supplements
- Safe:Multivitamins — Generally safe to take alongside Orforglipron. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know Orforglipron is working?
Strong human trials · first signs weeks 1-8
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved for this use — as FOUNDAYO (orforglipron) tablets, on 1 April 2026, for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition
Not approved for type 2 diabetes.
Onset of effects
Moderate
(1-2 weeks)
How it works
Orforglipron is a small-molecule (non-peptide) drug, taken as a once-daily pill, that activates the GLP-1 receptor — the same receptor injectable drugs like semaglutide act on — so people eat less, likely because appetite falls.
The deeper mechanism
Orforglipron is a non-peptide GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor.
[7] GLP-1 receptors are present in brain regions that regulate appetite; in animal studies orforglipron reached and activated neurons in those regions, and in people it decreases food intake, likely by decreasing appetite.
[7] It delays gastric emptying, most after the first dose and less over time, and the weight lost is more fat mass than lean mass. [7] It is metabolised mainly by hepatic CYP3A4, reaches peak concentration 4–8 hours after a dose, and has an elimination half-life of about 29–49 hours. [7]
What to expect
Weeks 1-8
What you might notice
- Dose escalation period from 3 mg to target maintenance
- GI side effects (nausea, constipation) peak during this phase
- Early appetite reduction and initial weight loss
What's normal
- Nausea is common and expected during dose titration
- Appetite naturally decreases as GLP-1R activation increases
- Early weight loss of 2-4% may occur
- GI symptoms gradually improve as the body adjusts
What's next
- Reach target maintenance dose (12 or 36 mg)
- GI tolerability typically improves significantly after dose stabilization
Weeks 8-24
What you might notice
- Steady weight loss acceleration at maintenance dose
- HbA1c improvements becoming measurable
- GI side effects largely resolved
- Reduced appetite stabilizes
What's normal
- Weight loss of 5-8% at this timepoint
- HbA1c dropping significantly in T2DM patients
- Blood pressure and lipid improvements beginning
- Most patients tolerate medication well
What's next
- Continue maintenance dose
- HbA1c assessment at 12-16 weeks reflects cumulative glycemic benefit
Weeks 24-72
What you might notice
- Continued weight loss approaching 10-12% at 36 mg
- Sustained metabolic improvements
- Cardiovascular risk markers (hsCRP, lipids, BP) showing significant improvement
What's normal
- In ATTAIN-1 trial, 12
- 4% weight loss at 36 mg over 72 weeks
- 65% of patients achieved >10% weight loss
- 6% reduction in hsCRP
- HbA1c reductions sustained
What's next
- Long-term maintenance
- Phase 3 cardiovascular outcomes trial (ATTAIN-Outcomes) will define long-term cardiovascular benefit
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Orforglipron over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked about Orforglipron
How is orforglipron different from injectable GLP-1 agonists like semaglutide?
Orforglipron is fundamentally different in three ways: (1) It's a small molecule pill, not an injectable peptide; (2) It binds to an allosteric (different) site on the GLP-1 receptor versus the orthosteric site used by peptide GLP-1 RAs; (3) It has G protein-biased signaling that may reduce receptor desensitization. The practical advantage is enormous — it has 77% absolute oral bioavailability [7] with no food or water restrictions, compared to injectable semaglutide which requires weekly injections, or oral semaglutide which has <1% bioavailability and requires 30 minutes of fasting.
Did orforglipron beat semaglutide in clinical trials?
Yes, in the head-to-head ACHIEVE-3 Phase 3 trial comparing orforglipron to oral semaglutide in type 2 diabetes patients, orforglipron 36 mg demonstrated superiority in both glycemic control (HbA1c -2.2% vs -1.4%) and weight loss (-9.2% vs -5.3%). Nearly 3 times more patients achieved HbA1c <7% with orforglipron 36 mg compared to semaglutide 14 mg.
When will orforglipron be available to prescribe?
Can patients switch from injectable GLP-1 RAs to orforglipron?
Early clinical data from the ATTAIN-Maintain trial suggests patients can successfully maintain weight loss when switching from injectable GLP-1 RAs to oral orforglipron. This represents a potentially significant clinical application — patients who achieve their goals with injections could transition to the convenience of an oral pill for long-term maintenance.
Does orforglipron require fasting before taking it?
No. Unlike oral semaglutide which requires taking on an empty stomach with no more than 4 ounces of water and waiting 30 minutes before eating, orforglipron can be taken at any time regardless of food intake. Its 77% absolute oral bioavailability is not affected by food to a clinically relevant degree [7], making it far more convenient for daily use.
Is orforglipron truly a peptide?
No, orforglipron is technically a peptidomimetic — a non-peptide small molecule (MW 883 Da) with an indole-oxadiazole core structure. It mimics the pharmacological effect of GLP-1 peptides without being a peptide itself. This distinction is important because its small-molecule nature enables high oral bioavailability (77% [7]), oral tablet formulation, easier manufacturing, and potentially lower production costs compared to peptide-based biologics.
Further reading
Orforglipron history & related research
History · since 2015
The Pill That Could Change Everything: A Small Molecule Revolution
Scientists finally cracked the code that everyone said was impossible — a tiny pill that acts like a GLP-1 injection, costs a fraction to make, and doesn't require an empty stomach. Meet orforglipron: the drug that could bring weight-loss treatment to millions who refused to take shots.
Read the full history of OrforglipronReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Orforglipron, on one page.